Published in Hepatitis Weekly, August 16th, 2004
"Characterization of new chemical entities for their potential to produce drug-drug interactions is an important aspect of early drug discovery screening," scientists in California explained.
In a study conducted by M.D. Green and colleagues at Merck Research Laboratories in San Diego, the "potential for three metabotropic glutamate receptor antagonists to interact with recombinant human CYPs was investigated."
"2-Methyl-6-(phenylethenyl) pyridine (SIB-1893), 2-methyl-6-(phenylethynyl) pyridine (MPEP) and 3-[2-methyl-1,3-thiazol-4-yl)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly